Licensing
Licensing
Bring high-speed expression in house
AdaptVAC
AdaptVAC
AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines.
Investor
Investor
ExpreS2ion Biotechnologies is registered at Nasdaq Stockholm First North
protein challenges
Custom Proteins
Complex human, parasite and viral proteins
Transfection Reagent
Transfection Reagent
Formulated and optimised for insect cell transfection

 

We're Here To Solve Your Biggest Protein Challenges

We are a team of highly experienced scientists specialised in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. We are driven by a very focused passion for helping our partners solve their most critical and unique recombinant protein challenges. Our stable and flexible ExpreS2 recombinant protein expression platform perfectly supports all phases of drug discovery, R&D and manufacturing.

Boost your R&D

Our ExpreS2 platform can provide you with the complex proteins you need for your research. Since we started our company in 2010, more than 250 proteins have been successfully expressed in our system. For some of these, the ExpreS2 system was the only system that was able to provide the correct form of the desired protein.

Enable or expedite your pipeline

Our team of experts can help you get the proteins you need fast. Because the ExpreS2 platform is seamless from R&D to commercial manufacturing, no bridging studies in protein expression, quality and activity are needed when starting with ExpreS2. With their unique characteristics and stable expression, S2 cells allow cell line development and process development to take place in parallel, saving time significantly. We also support your process transfer and regulatory needs.

Find out more about our ExpreSplatform and how to license it for in-house use.

Get in touch to discuss your challenge.